TTIP

Insufficient innovation and a lack of access to affordable medicines are major barriers to achieving the right to health in low- and middle-income countries.

The European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines, warn Oxfam and Health Action International.

Access to medicines poses a critical challenge in developing countries: prices are high, and new or adapted medicines and vaccines to address diseases of the developing world are lacking.